Natixis Advisors LLC Acquires 2,403 Shares of Amgen Inc. $AMGN

Natixis Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 341,057 shares of the medical research company’s stock after acquiring an additional 2,403 shares during the period. Natixis Advisors LLC’s holdings in Amgen were worth $96,246,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. West Family Investments Inc. lifted its holdings in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC increased its stake in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd raised its position in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the period. TAGStone Capital Inc. raised its position in Amgen by 0.8% during the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the period. Finally, BBR Partners LLC lifted its stake in shares of Amgen by 0.5% in the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock valued at $2,008,000 after purchasing an additional 32 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.5%

Shares of NASDAQ AMGN opened at $369.53 on Monday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm has a market cap of $199.20 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45. The business has a fifty day simple moving average of $353.26 and a two-hundred day simple moving average of $322.80. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent research reports. Barclays assumed coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price for the company. Piper Sandler increased their price target on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Rothschild & Co Redburn raised their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Morgan Stanley lifted their price objective on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $354.17.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.